Genelux (GNLX) Current Leases (2022 - 2026)

Genelux (GNLX) posted quarterly Current Leases of $316000.0 for Q1 2026, down 26.0% quarter-over-quarter from $427000.0 in Q4 2025.

Genelux (GNLX) Current Leases (2022 - 2026) Analysis & Trends

Genelux's Current Leases history runs 5 years deep, the most recent figure standing at $316000.0 for Q1 2026.

In Q1 2026, Current Leases changed N/A year-over-year to $316000.0; the TTM figure through Mar 2026 stood at $316000.0 (changed N/A YoY), while the FY2025 annual figure was $427000.0, up 29.79% from the prior year.
Current Leases for Q1 2026 stood at $316000.0, down from $427000.0 in the prior quarter.
The five-year high for Current Leases was $653000.0 in Q4 2023, with the low at $266000.0 in Q4 2022.
The 5-year median for Current Leases is $415000.0 (2024), against an average of $432363.6.
The sharpest annual moves came in 2023 and 2024: Current Leases soared 145.49% in 2023, then plunged 49.62% in 2024.
Genelux's Current Leases stood at $266000.0 in 2022, then surged by 145.49% to $653000.0 in 2023, then slumped by 49.62% to $329000.0 in 2024, then climbed by 29.79% to $427000.0 in 2025, then fell by 26.0% to $316000.0 in 2026.
Business Quant data shows GNLX's Current Leases at $316000.0 in Q1 2026, $427000.0 in Q4 2025, and $354000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Leases (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	720.00 Mn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	21.95 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	45.93 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	6.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-
10	Genelux	120.53 Mn	120.53 Mn	-	316,000.00

Download Data